Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
The bacterial CRISPR/Cas9 system allows sequence-specific gene editing in many organisms and holds promise as a tool to generate models of human diseases, for example, in human pluripotent stem cells. CRISPR/Cas9 introduces targeted double-stranded breaks (DSBs) with high efficiency, which are typically repaired by non-homologous end-joining (NHEJ) resulting in nonspecific insertions, deletions or other mutations (indels). DSBs may also be repaired by homology-directed repair (HDR) using a DNA repair template, such as an introduced single-stranded oligo DNA nucleotide (ssODN), allowing knock-in of specific mutations. Although CRISPR/Cas9 is used extensively to engineer gene knockouts through NHEJ, editing by HDR remains inefficient and can be corrupted by additional indels, preventing its widespread use for modelling genetic disorders through introducing disease-associated mutations. Furthermore, targeted mutational knock-in at single alleles to model diseases caused by heterozygous mutations has not been reported. Here we describe a CRISPR/Cas9-based genome-editing framework that allows selective introduction of mono- and bi-allelic sequence changes with high efficiency and accuracy. We show that HDR accuracy is increased dramatically by incorporating silent CRISPR/Cas-blocking mutations along with pathogenic mutations, and establish a method termed 'CORRECT' for scarless genome editing. By characterizing and exploiting a stereotyped inverse relationship between a mutation's incorporation rate and its distance to the DSB, we achieve predictable control of zygosity. Homozygous introduction requires a guide RNA targeting close to the intended mutation, whereas heterozygous introduction can be accomplished by distance-dependent suboptimal mutation incorporation or by use of mixed repair templates. Using this approach, we generated human induced pluripotent stem cells with heterozygous and homozygous dominant early onset Alzheimer's disease-causing mutations in amyloid precursor protein (APP(Swe)) and presenilin 1 (PSEN1(M146V)) and derived cortical neurons, which displayed genotype-dependent disease-associated phenotypes. Our findings enable efficient introduction of specific sequence changes with CRISPR/Cas9, facilitating study of human disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While exogenous DNA can be inserted at the target site through homology-directed repair (HDR) mechanism, successful insertion of exogenous DNA is relatively rare and is likely accompanied by loss of the second allele24.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [24]
In the citing paper
“Briefly, the majority of a HDR template’s homology arm sequences are not incorporated with on-target HDR integrations (Paquet et al., 2016)”
From Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies (2020) · cites this paper as Paquet et al., 2016
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
PEAR: a fast and accurate Illumina Paired-End reAd mergeR
Zhang, J., Kobert, K., Flouri, T., & Stamatakis, A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt593 · Cited by 4,497
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Goecks, J., Nekrutenko, A., Taylor, J., & The Galaxy Team (2010) · Genome Biology · doi:10.1186/gb-2010-11-8-r86 · Cited by 3,453
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Cited by
Items 901–935 of 935
Lee, Y. S. (2019) · theses.fr (ABES) · doi:10.70675/65d5a9daz9e88z43a5zb640zffa61798d4f1
Molecular mechanisms of action of MT-MMPs involved in the pathogenesis of Alzheimer’s disease
García‐González, L. (2020) · theses.fr (ABES) · doi:10.70675/a04672c0z1f4az472ezbcd5zbea446eac50c
Development of a functional assay for CHD7, a protein involved in CHARGE syndrome
Brajadenta, G. S. (2019) · theses.fr (ABES) · doi:10.70675/4fbb6e82ze10az420czadafze974d3fb997c
Castelot, R. (2024) · theses.fr (ABES) · doi:10.70675/c2a7ce1ez8caaz4593zbb3azae8add8055b5
Rare bi-allelic MEX3B mutations in childhood herpes simplex encephalitis
Kerrouche, N. (2024) · theses.fr (ABES) · doi:10.70675/a1c17eadz8e32z4ae6z8f5dzbe60fed472de
Ghosh, D., Mayer-Hamblett, N., & Kaizer, A. M. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2667329 · Cited by 1
Balistreri, A., Turner, N., Compher, J., Almaraz, M., Prabhavalkar, A., Chittal, S., Labra, S. R., Ezekiel, K., Baal, C., Kwong, C. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724352
“Briefly, isogenic hiPSC lines (WT and PSEN1 M146V /WT familial AD mutant) derived from a male donor were obtained from the Tessier-Lavigne laboratory and New York Stem Cell Foundation (Paquet et al. 2016).”
Liu, M., Chen, S., Wang, J., Meng, G., & Dong, C. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.04.015
“This observation contrasts with distance-dependent effects reported in some other systems [29].”
Yehia, G., Pan, J., Servinsky, L., Hong, X., & Romanienko, P. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729891 · Cited by 1
Cheng, Y., Zhang, L., Zeng, W., Kong, D., Li, J., Dang, X., Kosami, K.-I., & Miki, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9990603/v1
Labun, K., Rio, O., Dahal‐Koirala, S., Komisarczuk, A. Z., Valen, E., & Haapaniemi, E. M. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag409
“Although synonymous blocking variants are known to enhance precise editing efficiency [ 1 ], their introduction can carry unintended biological risks at the target locus.”
Delhaye, A., Băţăgui, V. S., Nysten, J. V., Troubleyn, D., & Vonesch, S. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.26.734799
LFPM inhibition of RING1-mediated p53R175H degradation drives oncogenesis in p53R175H-mutant cancers
Li, X., Wang, B., Wang, Z., Li, Y., Li, Y., Gao, Y., & Wang, X. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01805-7
Norris, S., Yeddula, S. G. R., Su, E., Vandeloecht, K., Saunders, S. E., Wang, Y., Boychuk, C. R., Arnold, W. D., Lorson, C. L., & Davis, D. J. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1833024
“Some alternative strategies for influencing allelic outcomes have been described, including the use of mixed donor templates or manipulation of the distance between the Cas9-induced double-strand break and the desired mutation site (Paquet et al., 2016).”
Gene editing of hematopoietic stem cells: applications and advances
Li, Q., Wang, H., He, Y., Hong, G., & Bao, G. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04251-w
“This can be prevented by deliberately introducing synonymous mutations within the seed sequence (PAM-proximal region) of the sgRNA [58].”
Tomita, K., Nishida, Y., Matsumoto, D., Ichikawa, K., Watanabe, S., Kawano, K., Sakuma, T., & Sawayama, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-64798-w
Roman, G., Lauritzen, K. H., Smolkova, B., Almaas, R., Sandset, P. M., Stavik, B., Sullivan, G. J., & Chollet, M. E. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11221-6
“Specifically, the target mutation should ideally be within 10 bp of the Cas9 cut site to avoid the marked decline in HDR efficiency associated with greater distances [30, 55, 56].”
InfluentialCRISPR-Mediated Gene Editing: Generating Gene Knockouts or Precision Base Changes in F0 Xenopus
Powell, S., & Martin, S. A. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5360-9_5
Production of Cell Models with Differential Zygosity Using CRISPR Base Editors
Zhang, S., & Hubbard, B. P. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5257-2_12
Novel therapies in Alzheimer’s disease
Pavăl, D., Căpățînă, O., & Stănculete, M. F. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.026
Costa, J. R., Li, Y., Ahrabi, S., Li, Z., Rapoz-D’Silva, T., Krulik, M. E., Hyseni, S., Morrow, G., Guo, Y., Look, A. T., et al. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104817
The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
Jia, D., Liu, X., Wang, D., He, X., Liang, X., & Peng, W. (2026) · Journal of Fungi · doi:10.3390/jof12090705
“Unexpectedly, Sanger sequencing confirmed that engineered PAM mutations were not found in edited progeny, in stark contrast to the stable heritability of such mutations documented in animal and plant studies [26–28].”
Gene editing technologies in poultry: advances, applications, and future prospects
Shuaib, M., Warsito, S. H., Lai, W., Ullah, O., MUKHTIAR, M., Sufyan, A., Mustofa, I., Abass, K. S., Uzair, M. S., Iqbal, M., et al. (2026) · World s Poultry Science Journal · doi:10.1080/00439339.2026.2734924
An Electroporation-Based Protocol for Ex Vivo Base Editing: From Design to Quantitative Assessment
Peña-Gutiérrez, I., Mazzeo, D., Bassons-Bascuñana, A., Haider, S., García‐García, L., Olalla-Sastre, B., Río, P., López-Manzaneda, S., & Mataix, M. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5547-4_19
Smith, E. D., Meisner, J. K., Bullard, A., Ward, C., Licata, J., Smith, C., Kelly, C. M., LaRochelle, Z. T., Friedline, S., Renberg, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.20.753023
Zhao, C., Cao, Y., & Martemyanov, K. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.16.752223
Protocol for non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells
Mamia, K., Sollano, A. S. M., Lundberg, V., Vakkilainen, S., Kekäläinen, E., Schalin-Jäntti, C., Leinonen, E., Fevang, B., Grönholm, J., Martelius, T., et al. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1817322
“In order to prevent Cas9 from re-cutting the edited strand (Okamoto et al., 2019; Paquet et al., 2016), we recommend integrating two to three synonymous SNVs into the ssODN design in addition to mutation correction (Figure 2) (Mamia et al., 2025).”
From Amyloid Exposure to Genetic Causality: Converging hiPSC-Based Models of Alzheimer’s Disease
Colasuonno, F., Valenza, A., Rossin, F., & Moreno, S. (2026) · Cells · doi:10.3390/cells15191793
“…who generated heterozygous and homozygous hiPSC lines carrying the APP Swedish (KM670/671NL) and PSEN1 M146V mutations, showing gene dosage-dependent increases in A β 42 production and A β 42/A β 40 ratios while validating the use of precise CRISPR-mediated engineering for disease modeling [74].”
Chen, X., Qin, S., Yang, C., Xing, Z., Liu, C., Zhang, X., Wu, X., Li, X., Gong, Y., & Liu, Z. (2026) · Cell Proliferation · doi:10.1111/cpr.70285
“However, multiple studies have reported that increased nuclease specificity or activity alone often has a minimal effect on HDR-mediated knock-in efficiency [33, 47].”
Edición genética: una valoración científica y bioética del primer caso en seres humanos en el Perú
Paredes-Moscosso, S. R., Villegas-Llerena, C., & Carbajal, C. Ñ. (2026) · Medicina y Ética · doi:10.36105/mye.2026v37n4.01
“Para salvar estas limitaciones, se ha demos - trado que el diseño (28,29) y elección de la cadena molde de repa-ración y su entrega (delivery) afectan en gran medida la eficiencia de HDR (27,30).”
Aliev, T., Imatdinov, A. R., Prudnikova, E. Y., & Иматдинов, И. Р. (2026) · Genes · doi:10.3390/genes17101247
Regulatory Elements and Splicing Factors Govern Mutually Exclusive Splicing of DmRdl Exon 3
Song, Z., Zhang, Y., Lin, K., Wang, X., Duan, Y., Bao, J., Bass, C., & Zhao, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219493
Metadata
- Authors
- Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M.
- Affiliations
- Rockefeller University (US)
- New York Stem Cell Foundation (US)
- Cornell University (US)
- Venue
- Nature
- Published
- 2016-04-27
- Volume
- 533
- Issue
- 7601
- Pages
- 125-129
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2343876552
- Cited by
- 951
- References
- 49
- Citations by year
- 2026: 58 · 2025: 56 · 2024: 90 · 2023: 87 · 2022: 104 · 2021: 106 · 2020: 125 · 2019: 93 · 2018: 111 · 2017: 91 · 2016: 29
- FWCI
- 56.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000043)
- National Institute of General Medical Sciences (T32GM007739)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, homology-directed repair, non-homologous end joining, amyloid precursor protein, presenilin 1, early-onset Alzheimer's disease, induced pluripotent stem cells, disease modeling
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Adolescent, Alleles, Alzheimer Disease, Animals, Base Sequence, DNA Repair, Female, Genes, Dominant, Genetic Engineering, Heterozygote, Homozygote, Humans, Male, Mutation, Substrate Specificity, Templates, Genetic, Mutagenesis, Amyloid beta-Protein Precursor, Sequence Homology, Age of Onset, Mice, Presenilins, DNA Cleavage, DNA Breaks, Double-Stranded, Genetic Association Studies, Induced Pluripotent Stem Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.